GTC 2023 Healthcare Special Address
Category: Healthcare Special Address · Year: 2023 · ▶ Watch
Segments (9)
- 00:00 · Introduction to Generative AI in Healthcare
- Kimberly Powell introduces the impact of generative AI across the healthcare ecosystem, from imaging to drug discovery.
- 02:30 · NVIDIA Clara and Ecosystem
- Overview of the NVIDIA Clara computing platform and its broad partner ecosystem.
- 04:05 · MONAI: The AI Factory for Imaging
- Deep dive into MONAI, its 1 million downloads milestone, and new generative AI models for medical imaging.
- 08:50 · NVIDIA Holoscan for Medical Devices
- Introduction of Holoscan and IGX Orin for real-time, software-defined AI processing at the edge.
- 12:12 · Medtronic Partnership
- Interview with Medtronic CEO Geoff Martha on building an AI platform for medical devices using Holoscan.
- 18:49 · Accelerating Genomics with Parabricks
- Updates on NVIDIA Parabricks 4.1, accelerating whole genome sequencing and supporting new sequencing platforms.
- 23:32 · Digital Biology and Drug Discovery
- How generative AI is turning biology into engineering, and the introduction of the BioNeMo cloud service.
- 27:38 · BioNeMo Service Demo
- A demonstration of the BioNeMo web interface for protein structure prediction and molecule generation.
- 33:30 · Tokyo-1 Supercomputer Announcement
- Announcement of Japan’s first pharmaceutical supercomputer in partnership with Mitsui & Co.
Product Announcements (6)
- [03:08] NVIDIA DGX Cloud for Healthcare
- Cloud-based AI supercomputing access
- specs: Available through Microsoft Azure, Google GCP, and Oracle OCI
- availability: Available now
- [11:11] Holoscan IGX Orin Developer Kits
- All-in-one industrial computer for medical edge AI
- specs: High-speed sensor input, ConnectX NIC, Orin SoC, RTX GPU
- availability: Available for order now
- [18:05] Medtronic GI Genius with Holoscan
- AI-assisted colonoscopy system
- specs: Adopts NVIDIA Holoscan and IGX for real-time AI enhanced imaging
- availability: Shipping at the end of the year
- [20:43] NVIDIA Parabricks 4.1
- Genomic analysis software suite
- specs: Whole genome sequencing in 16 mins, PacBio pipeline, DeepVariant fine-tuning
- availability: Available Q2 2023
- [27:00] NVIDIA BioNeMo Service
- Cloud service for generative AI in drug discovery
- specs: Pre-trained models for structure prediction, molecule generation, and docking
- availability: Early access now, general availability 2H 2023
- [33:34] Tokyo-1
- Pharmaceutical supercomputer in Japan
- specs: 16 NVIDIA DGX H100 nodes
- availability: Live in the second half of 2023
Specific Numbers (9)
| Timestamp | Metric | Value | Context |
|---|---|---|---|
| 05:25 | Downloads | 1,000,000 | Number of downloads for the MONAI framework. |
| 08:19 | Dollars | $500 billion | Annual cost of clinical trials. |
| 08:23 | Percentage | 90% | Failure rate of drug candidates. |
| 13:13 | Patients | 76 million | Number of patients served globally by Medtronic. |
| 15:46 | Percentage | 50% | Reduction in miss rate of polyps using Medtronic’s GI Genius. |
| 20:48 | Minutes | 16 | Time to complete whole genome sequencing analysis with Parabricks 4.1. |
| 26:18 | Dollars | $2 trillion | Approaching size of the pharmaceutical industry. |
| 26:34 | Years | 10 | Average time to get a new drug to market. |
| 31:02 | Time | 4 weeks | Time Amgen took to develop generative AI models using BioNeMo, down from 3 months. |
Benchmark Claims (3)
- [15:46] Polyp Miss Rate: Up to 50% reduction
- vs: Human-only colonoscopy
- gain: Significant improvement in early detection of potential colorectal cancer.
- [20:48] Whole Genome Sequencing Analysis Time: 16 minutes
- vs: 21 minutes (previous version)
- gain: 23% faster processing time.
- [31:27] Protein Structure Prediction Speed: 5x to 100x faster
- vs: Standard unoptimized models
- gain: Massive acceleration in biologics discovery workflows.
Customer Stories (5)
- [06:50] King’s College London
- Developed a latent diffusion model for generating synthetic brain imaging data.
- outcome: Enabled researchers to control global and regional brain volumes and adjust for age, gender, and disease.
- [08:13] Bristol Myers Squibb
- Used MONAI to build large foundation models for clinical trial outcomes.
- outcome: Created a semantic segmentation model to detect, classify, and measure patient data for consistent response assessment.
- [15:04] Medtronic
- Developed GI Genius, an AI-assisted colonoscopy module.
- outcome: Reduced the miss rate of polyps by up to 50% compared to human-only colonoscopy.
- [30:28] Amgen
- Used BioNeMo to customize property prediction models and generate proteins.
- outcome: Reduced model development time from 3 months to 4 weeks and ran structure prediction models up to 100x faster.
- [31:34] Deloitte
- Developed ProMAP, an intelligent structural drug discovery pipeline using BioNeMo APIs.
- outcome: Created an automated workflow that selects the best prediction model and refines structures for drug discovery.
Key Technologies (5)
- NVIDIA Clara: A suite of computing platforms, software, and services for healthcare applications.
- MONAI: Medical Open Network for AI, an open-source framework for building and deploying medical imaging AI.
- NVIDIA Holoscan: A real-time AI sensor processing platform for building software-defined medical devices.
- NVIDIA Parabricks: AI-accelerated genomic analysis software suite.
- NVIDIA BioNeMo: A cloud service providing generative AI models for drug discovery, including protein structure prediction and molecule generation.
Demos Shown (3)
- [06:34] Video demonstrating MONAI generative AI models, including latent diffusion for brain imaging and RadImageGAN.
- True
- [10:00] Video showing Holoscan processing real-time sensor data in surgical environments (endoscopy, ultrasound).
- True
- [27:38] Video demonstration of the BioNeMo web interface, showing protein structure prediction and molecule generation workflows.
- True
Predictions / Commitments (5)
- [13:31, Future] AI will help move upstream to less sick, high-risk people, increasing reach from 80 million to 800 million patients a year.
- [18:18, End of the year (2023)] Medtronic GI Genius with Holoscan will be shipping.
- [20:51, Q2 2023] Parabricks 4.1 will be available.
- [32:21, Second half of 2023] BioNeMo general availability.
- [34:22, Second half of 2023] Tokyo-1 supercomputer will be live.
Companies Mentioned (6)
Microsoft Azure, Google GCP, Oracle OCI · Amazon SageMaker · Arrow, PNY, Leadtek, Edom, Ryoyo, Macnica · Medtronic · Oxford Nanopore, PacBio · Mitsui & Co.
Notable Quotes (4)
Generative AI has become a human co-creation engine. — Kimberly Powell @ 01:33
It feels like it’s the Super Bowl for AI, and I couldn’t be more excited to be here. — Geoff Martha @ 12:59
For us to do this at scale and speed, to meaningfully impact society, we need AI. It’s that simple. — Geoff Martha @ 14:11
Generative AI is able to learn and represent biology, and it’s transforming biology from science to engineering. — Kimberly Powell @ 24:33
Key Topics
Generative AI · Healthcare · Medical Imaging · MONAI · Edge Computing · NVIDIA Holoscan · Medical Devices · Genomics · NVIDIA Parabricks · Drug Discovery · NVIDIA BioNeMo · Digital Biology · Supercomputing
Takeaways
- Generative AI is fundamentally transforming the healthcare industry, acting as a co-creation engine across imaging, genomics, and drug discovery.
- NVIDIA Clara provides a comprehensive, end-to-end AI computing platform tailored for the specific needs of healthcare and life sciences.
- MONAI has become an industry standard for medical imaging AI, surpassing 1 million downloads and introducing advanced generative models for synthetic data.
- NVIDIA Holoscan and IGX Orin enable the creation of software-defined medical devices capable of real-time AI processing at the edge.
- Medtronic is partnering with NVIDIA to integrate Holoscan into its medical devices, starting with the GI Genius system to improve colonoscopy outcomes.
- NVIDIA Parabricks continues to accelerate genomic analysis, reducing whole genome sequencing times and supporting new long-read technologies.
- The new NVIDIA BioNeMo cloud service democratizes access to state-of-the-art generative AI models for drug discovery, significantly speeding up the R&D process.
- Major pharmaceutical companies like Amgen are already leveraging BioNeMo to reduce model development time from months to weeks.
- The Tokyo-1 supercomputer initiative will provide dedicated AI computing power to accelerate pharmaceutical research and development in Japan.